Harrow (HROW) Net Income towards Common Stockholders (2010 - 2026)
Harrow (HROW) posted quarterly Net Income towards Common Stockholders of -$27.6 million for Q1 2026, down 55.24% year-over-year from -$61.7 million in Q1 2025, and down 365.48% quarter-over-quarter from $10.4 million in Q4 2025.
Harrow (HROW) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Harrow's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$27.6 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 55.24% year-over-year to -$27.6 million; the TTM figure through Mar 2026 stood at -$11.2 million (up 48.42% YoY), while the FY2025 annual figure was -$5.1 million, up 70.6% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$27.6 million, down from $10.4 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $10.4 million in Q4 2025, with the low at -$27.6 million in Q1 2026.
- The 5-year median for Net Income towards Common Stockholders is -$4.4 million (2023), against an average of -$5.0 million.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders tumbled 1223.5% in 2022, then surged 177.17% in 2025.
- Harrow's Net Income towards Common Stockholders stood at $1.1 million in 2022, then sank by 967.11% to -$9.1 million in 2023, then jumped by 174.08% to $6.8 million in 2024, then jumped by 53.42% to $10.4 million in 2025, then sank by 365.48% to -$27.6 million in 2026.
- Business Quant data shows HROW's Net Income towards Common Stockholders at -$27.6 million in Q1 2026, $10.4 million in Q4 2025, and $1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Harrow | 1.54 Bn | 1.46 Bn | 50.36 Mn | -17.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.27 Mn |
| Mar 31, 2026 | -27.60 Mn |
| Dec 31, 2025 | 10.40 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Mar 31, 2025 | -17.78 Mn |
| Dec 31, 2024 | 6.78 Mn |
| Sep 30, 2024 | -4.22 Mn |
| Jun 30, 2024 | -6.47 Mn |
| Mar 31, 2024 | -13.57 Mn |
| Dec 31, 2023 | -9.15 Mn |
| Sep 30, 2023 | -4.39 Mn |
| Jun 30, 2023 | -4.23 Mn |
| Mar 31, 2023 | -6.64 Mn |
| Dec 31, 2022 | 1.06 Mn |
| Sep 30, 2022 | -6.46 Mn |
| Jun 30, 2022 | -6.24 Mn |
| Mar 31, 2022 | -2.44 Mn |
| Dec 31, 2021 | -7.42 Mn |
| Sep 30, 2021 | -8.33 Mn |